Early research (Phase 1)Looking for participantsNCT06980116
What this trial is testing
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Who this might be right for
Relapsed or Refractory B-cell MalignanciesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 85